SYROS PHARMACEUTICALS INC's ticker is SYRS and the CUSIP is 87184Q107. A total of 70 filers reported holding SYROS PHARMACEUTICALS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $106,000 | -68.5% | 88,811 | -14.0% | 0.00% | -50.0% |
| Q4 2021 | $337,000 | -25.8% | 103,310 | +1.6% | 0.00% | -33.3% |
| Q3 2021 | $454,000 | +95.7% | 101,646 | +138.9% | 0.00% | +50.0% |
| Q2 2021 | $232,000 | -50.8% | 42,555 | -32.6% | 0.00% | -50.0% |
| Q1 2021 | $472,000 | -64.5% | 63,108 | -48.5% | 0.00% | -66.7% |
| Q4 2020 | $1,330,000 | +146.3% | 122,600 | +100.7% | 0.01% | +100.0% |
| Q3 2020 | $540,000 | -24.9% | 61,094 | -9.4% | 0.01% | -25.0% |
| Q2 2020 | $719,000 | +89.2% | 67,422 | +5.3% | 0.01% | +60.0% |
| Q1 2020 | $380,000 | +21.8% | 64,058 | +41.7% | 0.01% | +66.7% |
| Q4 2019 | $312,000 | +109.4% | 45,220 | +177.8% | 0.00% | +50.0% |
| Q1 2019 | $149,000 | -73.9% | 16,275 | -84.1% | 0.00% | -80.0% |
| Q4 2018 | $571,000 | -39.2% | 102,459 | +29.9% | 0.01% | -23.1% |
| Q3 2018 | $939,000 | +19.9% | 78,859 | +2.9% | 0.01% | +8.3% |
| Q2 2018 | $783,000 | +368.9% | 76,659 | +346.5% | 0.01% | +300.0% |
| Q4 2017 | $167,000 | – | 17,170 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Flagship Pioneering Inc. | 4,806,656 | $58,449,000 | 19.02% |
| Casdin Capital, LLC | 182,141 | $2,215,000 | 1.83% |
| Aisling Capital LLC | 508,565 | $6,184,000 | 1.44% |
| Redmile Group, LLC | 948,440 | $11,533,000 | 0.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,812,778 | $22,043,000 | 0.91% |
| EcoR1 Capital, LLC | 63,596 | $773,000 | 0.25% |
| Eventide Asset Management | 150,000 | $1,824,000 | 0.12% |
| AWM Investment Company, Inc. | 47,550 | $578,000 | 0.11% |
| Weiss Multi-Strategy Advisers LLC | 49,000 | $596,000 | 0.03% |
| Baker Brothers Advisors | 204,465 | $2,486,000 | 0.02% |